Evidence map›Paper›PMID 29416543›Full record

ArticleFrontiers in immunology2018

Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection.

Tatsuya Yamazaki, Maria Nagashima, Daisuke Ninomiya, Akira Ainai, Akira Fujimoto, Isao Ichimonji, Hidekazu Takagi, Naoko Morita, Kenta Murotani, Hideki Hasegawa and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Antiviral Approaches against Influenza Virus.Clinical microbiology reviews · 2023
    Review
  4. Review
  5. Article
  6. Receptor-destroying enzyme (RDE) fromThe Journal of biological chemistry · 2019
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Tatsuya YamazakiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Nagakute, Japan.
Maria NagashimaDepartment of Biological Science and Technology, Tokyo University of Science, Katsushika, Japan.
Daisuke NinomiyaDepartment of Biological Science and Technology, Tokyo University of Science, Katsushika, Japan.
Akira AinaiDepartment of Pathology, National Institute of Infectious Diseases, Shinjuku, Japan.
Akira FujimotoDepartment of Biological Science and Technology, Tokyo University of Science, Katsushika, Japan.
Isao IchimonjiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Nagakute, Japan.
Hidekazu TakagiDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Nagakute, Japan.
Naoko MoritaDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Nagakute, Japan.
Kenta MurotaniDivision of Biostatistics, Clinical Research Center, School of Medicine, Aichi Medical University, Nagakute, Japan.
Hideki HasegawaDepartment of Pathology, National Institute of Infectious Diseases, Shinjuku, Japan.
Joe ChibaDepartment of Biological Science and Technology, Tokyo University of Science, Katsushika, Japan.
Sachiko Akashi-TakamuraDepartment of Microbiology and Immunology, School of Medicine, Aichi Medical University, Nagakute, Japan.
Aichi Medical University · JPTokyo University of Science · JPNational Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influenza virus causes annual epidemics and occasional pandemics and is thus a major public health problem. Development of vaccines and antiviral drugs is essential for controlling influenza virus infection. We previously demonstrated the use of vectored immune-prophylaxis against influenza virus infection. We generated a plasmid encoding neutralizing IgG monoclonal antibodies (mAbs) against A/PR/8/34 influenza virus (IAV) hemagglutinin (HA). We then performed electroporation of the plasmid encoding neutralizing mAbs (EP) in mice muscles and succeeded in inducing the expression of neutralizing antibodies in mouse serum. This therapy has a prophylactic effect against lethal IAV infection in mice. In this study, we established a new method of passive immunotherapy after IAV infection. We performed hydrodynamic injection of the plasmid encoding neutralizing mAbs (HD) involving rapid injection of a large volume of plasmid-DNA solution into mice

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralElectroporationFemaleHemagglutinin Glycoproteins, Influenza VirusHydrodynamicsImmunization, PassiveInfluenza VaccinesInjectionsMice, Inbred BALB COrthomyxoviridae InfectionsPlasmidsRespiratory MucosaAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccinesgene therapyhemagglutininhydrodynamics procedureinfluenzaneutralizing antibodypassive immunotherapy

Identifiers

PMID29416543
PMCPMC5787536
OpenAlexW2792411592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.